Thermo Fisher Revenue Reaches Beyond $40 Billion

With total earnings reaching more than $40 billion, Thermo Fisher Scientific is positioned as the market front runner in scientific service and innovation.

Last year, sales for Q4 increased by 7% to $11.45 billion, compared to $10.70 billion in the same period the year prior.

Income directly related to Covid testing during the pandemic was $370 million, with organic sales declining by 3% and core organic sales increasing by 14%.

In 2022’s Q4, GAAP operating income was $1.9 billion as opposed to $2.5 billion during the same period in 2021. Diluted net income per share also dipped slightly, at $4.2 in Q4 2021 just over $4 in Q4 2022. The GAAP operating margin dropped from almost 24% to less than 16.5% in the same timeframe.

Other figure comparisons for Q4 include the EPS after adjustments, which dropped $1.1 from $6.5 to $5.4, the adjusted operating earnings dropping from $3.2 billion to $2.7 billion, and adjusted operating margin also falling from 29.5% to 22.4%.

One project Thermo is initiating for 2023 is providing advice regarding sales and adjusted EPS.

The business projects core organic sales growth of 7% this fiscal year with total earnings of $45.3 billion. The business anticipates generating an adjusted EPS of $23.7.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.